1. Obiltoxaximab Drugbank ID :DB05336 Molecular Weight (Daltons) :148000
Description :
Obiltoxaximab, an affinity-enhanced monoclonal antibody (Mab), is used for prevention and treatment of infection and death caused by anthrax toxin. Obiltoxaximab is a chimeric IgG1 kappa monoclonal antibody (mAb) that binds the PA component of B. anthracis toxin. It has an approximate molecular weight of 148 kDa.

2. Indication :
Investigated for use/treatment in anthrax exposure, bacterial infection, crohn's disease, and graft versus host disease.
Pharmacodynamics : NA
Mechanism of action :
ETI-204 is an affinity-enhanced, de-immunized antibody, which means that its ability to bind to its target pathogen has been strengthened and that elements that might cause an immune response have been removed. ETI-204 targets and binds to Protective Antigen, which prevents the anthrax toxins from binding to and entering the cells in the body, thereby preventing death.

3. Metabolism :NA
Absorption : Mean Cmax and AUCinf were 400 ± 91.2 mcg/mL and 5170 ± 1360 mcg•day/mL, respectively.
Volume of distribution :NA
Clearance :NA
Categories : NA
Patents : NA
Brands : Anthim
Company : Elusys Therapeutics, Inc.
Formulation : Solution
Form : Liquid
Route of administration : Intravenous infusion

4. Dosage : The recommended dosage of ANTHIM in adult patients is a single dose of 16 mg/kg administered intravenously over 90 minutes (1 hour and 30 minutes); For adult patients weighing less than 40 kg. Contraindication : NA Side effects : Hypersensitivity and Anaphylaxis

5. Useful links